Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis

Journal of Neurochemistry

Volumn 108, Issue 1, 2009, Pages 158-164

  Markianos, Manolis ^a   Koutsis, Georgios ^a   Evangelopoulos, Maria Eleftheria ^a   Mandellos, Dimitrios ^a   Karahalios, Georgios ^a   Sfagos, Constantin ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

CSF metabolites; Dopamine; Expanded disability status scale; Multiple sclerosis; Multiple sclerosis severity score; Noradrenaline; Serotonin

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; NEUROTRANSMITTER; NORADRENALIN; SEROTONIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; SCORING SYSTEM; SEROTONINERGIC SYSTEM;

ADOLESCENT; ADULT; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROTRANSMITTER AGENTS; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 57249086439     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05750.x     Document Type: Article

References (30)

1. Andersen O., Johansson B. B. Svennerholm L. (1981) Monoamine metabolites in successive samples of spinal fluid. A comparison between healthy volunteers and patients with multiple sclerosis. Acta Neurol. Scand. 63, 247 254.
2. Bjartmar C., Wujek J. R. Trapp B. D. (2003) Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206, 165 171.
3. Capuron L., Ravaud A., Neveu P. J., Miller A. H., Maes M. Dantzer R. (2002) Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 7, 468 473.
4. Chwastiak L., Ehde D. M., Gibbons L. E., Sullivan M., Bowen J. D. Kraft G. H. (2002) Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am. J. Psychiatry 159, 1862 1868.
5. Confavreux C. Vukusic S. (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129, 606 616.
6. Dantzer R., O'Connor J. C., Freund G. G., Johnson R. W. Kelley K. W. (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46 56.
7. Davidson D., Pullar I. A., Mawdsley C., Kinloch N. Yates C. M. (1977) Monoamine metabolites in cerebrospinal fluid in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 40, 741 745.
8. De Stefano N., Matthews P. M., Fillippi M. et al. (2003) Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 60, 1157 1162.
9. DeLuca G. C., Ebers G. C. Esiri M. M. (2004) Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 127, 1009 1018.
10. Dunn A. J. (2006) Effects of cytokines and infections on brain neurochemistry. Clin. Neurosci. Res. 6, 52 68.
11. Feinstein A., Roy P., Lobaugh N., Feinstein K., O'Connor P. Black S. (2004) Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 62, 586 590.
12. Heyes M. P., Saito K., Crowley J. S. et al. (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115, 1249 1273.
13. Kurtzke J. F. (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33, 1444 1452.
14. Little J. T., Ketter T. A., Mathe A., Frye M. A., Luckenbaugh D. Post R. M. (1999) Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression. Biol. Psychiatry 45, 285 289.
15. Loder C., Allawi J. Horrobib D. F. (2002) Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B12: mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems. Med. Hypotheses 59, 594 602.
16. Lublin F. D. Reingold S. C. (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46, 907 911.
17. Maes M., Lin A., Kenis G., Egved B. Bosmans E. (2000) Negative immunoregulatory effects of noradrenaline through alpha2-adrenoceptor activation. Neuro Endocrinol. Lett. 21, 375 382.
18. Mostert J. P., Admiraal-Behloul F., Hoogduin J. M., Luyendijk J., Heersena D. J., van Buchen M. A. De Keyser J. (2008) Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J. Neurol. Neurosurg. Psychiatry 79, 1027 1031.
19. Opitz C. A., Wick W., Steinman L. Platten M. (2007) Tryptophan degradation in autoimmune diseases. Cell. Mol. Life Sci. 64, 2542 2563.
20. Petzold A., Eikelenboom M. J., Keir G., Grant D., Lazeron R. H., Polman C. H., Uitdehaag B. M., Thompson E. J. Giovannoni G. (2005) Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J. Neurol. Neurosurg. Psychiatry 76, 206 211.
21. Petzold A., Eikelenboom M. J., Keir G., Polman C. H., Uitdehaag B. M., Thompson E. J. Giovannoni G. (2006) The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers. Mult. Scler. 12, 325 328.
22. Pirko I., Lucchinetti C. F., Sriram S. Bakshi R. (2007) Gray matter involvement in multiple sclerosis. Neurology 68, 634 642.
23. Polman C. H., Reingold S. C., Edan G. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58, 840 846.
24. Roxburgh R. H., Seaman S. R., Masterman T. et al. (2005) Multiple Sclerosis Severity Score. Using disability and disease duration to rate disease severity. Neurology 64, 1144 1151.
25. Sabatini U., Pozzilli C., Pantano P. et al. (1996) Involvement of the limbic system in multiple sclerosis patients with depressive disorders. Biol. Psychiatry 39, 970 975.
26. Schiepers O. J. G., Wichers M. C. Maes M. (2005) Cytokines and major depression. Prog. Neuropsychopharmcol. Biol. Psychiatry 29, 201 217.
27. Siegert R. J. Abernethy D. A. (2005) Depression in multiple sclerosis: a review. J. Neurol. Neurosurg. Psychiatry 76, 469 475.
28. Tellez N., Alonso J., Rio J., Tintore M., Nos C., Montalban X. Rovira A. (2008) The basal ganglia: a substrate for fatigue in multiple sclerosis. Neuroradiology 50, 17 23.
29. Turner B., Lin X., Calmon G., Roberts N. Blumhardt L. D. (2003) Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult. Scler. 9, 21 27.
30. Wirleitner B., Neurauter G., Schroecksnadel K., Frick B. Fuchs D. (2003) Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr. Med. Chem. 10, 1381 1391.